Differential induction of LRP16 by liganded and unliganded estrogen receptor alpha in SKOV3 ovarian carcinoma cells.
Previously, we investigated the induction effect of LRP16 expression by estrogen (17beta-estradiol, E(2)) and established a feed-forward mechanism that activated estrogen receptor alpha (ERalpha) transactivation in estrogen-dependent epithelial cancer cells. LRP16 is required for ERalpha signaling transduction by functioning as an ERalpha coactivator. In this study, we demonstrated that LRP16 expression was upregulated in E(2)-responsive BG-1 ovarian cancer cells, but was downregulated in estrogen-resistant SKOV3 ovarian cancer cells. Pure estrogen antagonist ICI 182 780 did not affect LRP16 expression in SKOV3 cell. The unliganded ERalpha upregulated LRP16 expression and enhanced LRP16 promoter activity in SKOV3 cells; however, this induction was blocked by estrogen stimulation. Results from chromatin immunoprecipitation experiment revealed a strong recruitment of the unliganded ERalpha at LRP16 promoter in the absence of estrogen; however, ERalpha was largely released from the DNA upon E(2) stimulation. Modulation in LRP16 expression level did not significantly change the proliferation rate of SKOV3 cells and the growth responsiveness of cells to E(2). Knockdown of LRP16 by RNA interference in SKOV3 cells markedly attenuated estrogen response element-dependent ERalpha reporter gene activity and E(2)-induced c-Myc expression. Our study suggests a novel mechanism of estrogen resistance of ovarian cancer by which estrogen-repressed signaling pathway antagonizes estrogen-activated signaling transduction.
Tian
Liyuan
L
Department of Molecular Biology, Institute of Basic Medicine, Chinese PLA General Hospital, Beijing, People's Republic of China.
Wu
Zhiqiang
Z
Zhao
Yali
Y
Meng
Yuanguang
Y
Si
Yiling
Y
Fu
Xiaobing
X
Mu
Yiming
Y
Han
Weidong
W
D002265:Carboxylic Ester Hydrolases; D002277:Carcinoma / Q000235:genetics* / Q000473:pathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004958:Estradiol / Q000378:metabolism / Q000494:pharmacology*; D047628:Estrogen Receptor alpha / Q000378:metabolism / Q000502:physiology*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D008024:Ligands; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000473:pathology; D011401:Promoter Regions, Genetic / Q000187:drug effects; D011485:Protein Binding / Q000187:drug effects; D034741:RNA, Small Interfering / Q000494:pharmacology; D015398:Signal Transduction / Q000187:drug effects / Q000235:genetics; D014162:Transfection; D015854:Up-Regulation / Q000187:drug effects
D047628:Estrogen Receptor alpha; D008024:Ligands; D009363:Neoplasm Proteins; D034741:RNA, Small Interfering; D004958:Estradiol; D002265:Carboxylic Ester Hydrolases; C476832:MACROD1 protein, human